Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959 | 0.76 | SLC9A1 (0.48) | — | |
| SCHEMBL34213 | 0.73 | — | — | |
| SCHEMBL10552820 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL5438355 | 0.72 | ALDH1A1 (0.44) | MAPK1MAPTKDM4E | |
| SCHEMBL2871727 | 0.71 | MGAM (0.43) | KDM4E | |
| SCHEMBL2866375 | 0.70 | TDO2 (0.39) | MAPK1LMNAMAPTKDM4E | |
| SCHEMBL15155876 | 0.69 | SLC9A1 (0.56) | LMNAMAPT | |
| SCHEMBL2207685 | 0.68 | RAB9A (0.35) | POLBMAPK1PKMLMNAKDM4E | |
| SCHEMBL4006348 | 0.68 | TSHR (0.41) | PKMLMNAMAPT | |
| SCHEMBL6756160 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154724-A2 | PROCESSES AND COMPOUNDS FOR PREPARING SPIROLIGOMERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-08-17 | — | — | WO | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113423430-A | Amanitoxin conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2021-09-21 | — | — | CN | claimed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-111093707-A | Tubulysin homolog conjugates containing branched linkers | 杭州多禧生物科技有限公司 | 2020-05-01 | — | — | CN | claimed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | claimed |
| US-20190216940-A1 | Prodrugs Comprising a Pyroglutamate Linker | ASCENDIS PHARMA A/S (DK) | 2019-07-18 | — | — | US | claimed |
| EP-3303365-A2 | PRODRUGS COMPRISING A PYROGLUTAMATE LINKER | Ascendis Pharma Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| WO-1999033483-A1 | TRIALKYL-LOCK-FACILITATED POLYMERIC PRODRUGS OF AMINO-CONTAINING BIOACTIVE AGENTS | ENZON, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999030727-A1 | POLYMERIC PRODRUGS OF AMINO- AND HYDROXYL-CONTAINING BIOACTIVE AGENTS | ENZON, INC. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-0573289-B1 | Process for preparation of 2-oxo-1-piperidinyl derivatives | BRACCO INT BV (NL) | 1999-04-28 | — | — | EP | claimed |
| US-5824701-A | Taxane-based prodrugs | ENZON, INC. (US) | 1998-10-20 | — | — | US | claimed |
| US-5622986-A | 2'-and/or 7-substituted taxanes | ENZON, INC. (US) | 1997-04-22 | — | — | US | claimed |
| US-5559237-A | Process for preparation of 2-oxo-1-piperidinyl derivatives | BRACCO INTERNATIONAL B.V. (NL) | 1996-09-24 | — | — | US | claimed |
| US-5359077-A | Process for preparation of 2-oxo-1 piperidinyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-25 | — | — | US | claimed |
| EP-0609899-A1 | Derivatives of amino-ascorbic acid,the processes for their preparation and use | PLIVA FARMACEUTSKA KEMIJSKA PREHRAMBENA I KOZMETICKA INDUSTRIJA DIONICKO DRUSTVO ZAGREB (HR) | 1994-08-10 | — | — | EP | claimed |
| US-4089868-A | Sulfonium salt substantive sunscreen materials | COLGATE-PALMOLIVE COMPANY (US) | 1978-05-16 | — | — | US | claimed |
| US-4022829-A | INTERMEDIATES FOR SUNSCREEN AGENTS | COLGATE-PALMOLIVE COMPANY (US) | 1977-05-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216940-A1 | Prodrugs Comprising a Pyroglutamate Linker | GLS, GLUL, FPGS | POLB 1844/4885MAPK1 3510/4885ATM 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.